X

Drug Profile

BDC 4182

Alternative Names: BD-4182; BDC4182

Latest Information Update: 21 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bolt Biotherapeutics
Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Gastric cancer; Oesophageal cancer; Pancreatic cancer

Most Recent Events

12 Nov 2024 Bolt Biotherapeutics plans a clinical trial in the second quarter of 2025
07 Nov 2024 Pharmacodynamics data from preclinical trial in Solid tumours were released by Bolt Biotherapeutics
14 May 2024 Preclinical trials in Gastric cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com